PHOENIX--(BUSINESS WIRE)--Synovics Pharmaceuticals, Inc. (OTCBB:SYVC), a specialty pharmaceutical company, today announced that it has entered into a marketing and consulting agreement with VCG & A, Inc. (“VCG”), a leading pharmaceutical industry consultant company that provides relationship-driven market access to increase product market share and sales. Under terms of the agreement VCG will target major retail chains, national wholesalers, managed care organizations and government agencies for sales of Synovics’ subsidiary, Kirk Pharmaceuticals, current OTC and prescription drug products and potential sales of drugs in the Company’s product pipeline. In addition, Synovics will gain access to development and marketing rights of VCG’s proprietary drug candidates.
